Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Nguyenla, Xammy Huu ; Bates, Timothy A. ; Trank-Greene, Mila ; Wahedi, Mastura ; Tafesse, Fikadu G. ; Curlin, Marcel
• Description:
  Because novel SARS-CoV-2 variants continue to emerge, immunogenicity of XBB.1.5 monovalent vaccines against live clinical isolates needs to be evaluated. We report boosting of IgG (2.1×), IgA (1.5×), and total IgG/A/M (1.7×) targeting the spike receptor-binding domain and neutralizing titers against WA1 (2.2×), XBB.1.5 (7.4×), EG.5.1 (10.5×), and JN.1 (4.7×) variants.
• Subjects:
  Adult Antibodies, Neutralizing Antibodies, Viral COVID-19 COVID-19 Vaccines Female Humans Immunity, Humoral Immunogenicity, Vaccine Immunoglobulin A Immunoglobulin G SARS-CoV-2 Spike Glycoprotein, Coronavirus

  More +
• Keywords:
  Allergy And Immunology Antibodies Coronavirus Coronavirus Disease Respiratory Infections SARS Severe Acute Respiratory Syndrome Coronavirus 2 United States Vaccines Viruses
• Source:
  Emerg Infect Dis. 2024; 30(6):1283-1285
• Pubmed ID:
  38669121
• Pubmed Central ID:
  PMC11138983
• Document Type:
  Journal Article
• Genre:
  Research Letter
• Volume:
  30
• Issue:
  6
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:c93762c026963de1020f6234c679d244717accc12c7d6537331b89274d7d1903
• Download URL:
  https://stacks.cdc.gov/view/cdc/156995/cdc_156995_DS1.pdf
• File Type:
  [PDF - 924.15 KB ]